Twenty-two out of 63 PD patients were taking the CYP1A2-substrate rasagiline, and these patients showed significantly higher basal caffeine levels as compared to those who were not (U = 913, p = 0.03). This evidence concerns the gene CYP1A2 and Parkinson disease.